The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2020 | Developing T-cell based therapies for CLL treatment
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses T-cell based therapy to treat chronic lymphocytic leukemia (CLL). Prof. Kater emphasizes how we can develop these therapies to improve function and that we need to set realistic goals for CLL treatment. Additionally, Prof. Kater discusses a synergistic approach of CLL targeting with both CAR T-cells and ibrutinib. However, whether the concurrent treatment of patients with both drugs really results in superior responses is still a matter of debate. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
